Last reviewed · How we verify
NCT06944587: NORPACT-3
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
trial testing Chemotherapy in Locally Advanced Pancreatic Cancer in 400 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 3 December 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 5 locations across Norway |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
- Radiology
- Pancreatectomy
- Endoscopy
Conditions studied
- Locally Advanced Pancreatic Cancer — all drugs for Locally Advanced Pancreatic Cancer →
- Borderline Resectable Pancreatic Cancer — all drugs for Borderline Resectable Pancreatic Cancer →
- Pancreatectomy — all drugs for Pancreatectomy →
- Chemotherapy Effect — all drugs for Chemotherapy Effect →
Sponsor
Oslo University Hospital
Who can join
18 and older, any sex, with Locally Advanced Pancreatic Cancer or Borderline Resectable Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06944587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other recruiting trials for Locally Advanced Pancreatic Cancer
Currently open trials in the same condition.
- NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
- NCT06494514 — NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line · NA · recruiting
- NCT05975593 — MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial · NA · recruiting
- NCT05653453 — Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatme · Phase 3 · recruiting
- NCT07407231 — Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic · NA · recruiting
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06944587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 25 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06944587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing